首页> 外文学位 >Cutaneous clear cell squamous cell carcinoma in situ: Clinical, morphological and immunohistochemical characterization.
【24h】

Cutaneous clear cell squamous cell carcinoma in situ: Clinical, morphological and immunohistochemical characterization.

机译:皮肤透明细胞鳞状细胞癌原位:临床,形态学和免疫组化特征。

获取原文
获取原文并翻译 | 示例

摘要

Clear cell squamous cell carcinoma in situ (clear cell SCCIS) has not been defined in the literature. The goals of this thesis is first, to review the literature on clear cell lesions of the skin and discuss the importance of the differential diagnosis; second, to characterize the clinical and histological features of clear cell squamous cell carcinoma in situ, and third, to define the special histochemical and immunohistochemical features of clear cell SCCIS to elucidate the type of cell differentiation and help distinguish it from other clear cell neoplasms of the skin. Clear cell SCCIS must be distinguished from other clear cell neoplasms of the skin to avoid misdiagnosis and increased burden of patient and physician time and medical expenses. Eighty-one cases of SCCIS with ≥5% clear cell change were identified among 1497 cases of SCCIS over an 18 month period and represented 5.5% of all SCCIS. Clear cell SCCIS was defined as having ≥95% clear cell change. It represented only 0.15% of SCCIS. The clinical features of all SCCIS with clear cell change, including age, sex and site distribution did not vary significantly from typical SCCIS using chi square analysis. Periodic acid-Schiff special staining and immunohistochemical analysis indicated that the clear cells in clear cell SCCIS differentiate toward outer root sheath cells. Antibodies most useful in labeling outer root sheath cells and SCCIS with clear cell changes were K 8.12 (labeling CK 13 and CK 16) in 100% of cases, cellular retinoic acid binding protein II (CRABP II) in 83% of cases, CAM 5.2 in 58% of cases and CK15 in 50% of cases. This study defines clear cell SCCIS on the end of the spectrum of SCCIS with clear cell change and this spectrum displays ORS differentiation.
机译:文献中尚未定义原位透明细胞鳞状细胞癌(透明细胞SCCIS)。本文的目的是:首先,回顾有关皮肤透明细胞病变的文献,并讨论鉴别诊断的重要性。其次,原位描述透明细胞鳞状细胞癌的临床和组织学特征;第三,定义透明细胞SCCIS的特殊组织化学和免疫组织化学特征,以阐明细胞分化的类型,并帮助将其与其他透明细胞瘤区分开。皮。透明细胞SCCIS必须与皮肤的其他透明细胞肿瘤区分开,以避免误诊以及增加患者和医生的时间和医疗费用负担。在18个月的时间里,在1497例SCCIS病例中,发现了81例SCCIS,其透明细胞变化≥5%,占所有SCCIS的5.5%。透明细胞SCCIS被定义为具有≥95%的透明细胞变化。它仅占SCCIS的0.15%。使用卡方分析,所有具有明显细胞变化的SCCIS的临床特征(包括年龄,性别和部位分布)与典型的SCCIS相比均无显着差异。高碘酸-希夫(Schiff)特殊染色和免疫组化分析表明,透明细胞SCCIS中的透明细胞向外根鞘细胞分化。在标记外根鞘细胞和SCCIS中具有明显的细胞变化最有用的抗体在100%的病例中是K 8.12(标记CK 13和CK 16),在83%的病例中是细胞视黄酸结合蛋白II(CRABP II),CAM 5.2 58%的病例和CK15的50%病例。这项研究在具有清晰细胞变化的SCCIS光谱末端定义了透明细胞SCCIS,该光谱显示了ORS分化。

著录项

  • 作者单位

    Boston University.;

  • 授予单位 Boston University.;
  • 学科 Pathology.;Cellular biology.
  • 学位 Ph.D.
  • 年度 2005
  • 页码 156 p.
  • 总页数 156
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号